Maria U Romer
Overview
Explore the profile of Maria U Romer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jensen N, Stenvang J, Beck M, Hanakova B, Belling K, Do K, et al.
Mol Oncol
. 2015 Mar;
9(6):1169-85.
PMID: 25759163
Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens with one of the two chemotherapeutic drugs, irinotecan or oxaliplatin. However, drug resistance frequently limits the clinical...
2.
Harslund J, Frees D, Leifsson P, Offenberg H, Romer M, Brunner N, et al.
Pathog Dis
. 2013 Jun;
68(3):96-104.
PMID: 23776165
Staphylococcus aureus is a common cause of skin and soft tissue infections in animal and humans. In the current study, we hypothesized that early host responses to S. aureus infection...
3.
Rasmussen M, Jensen N, Tarpgaard L, Qvortrup C, Romer M, Stenvang J, et al.
Mol Oncol
. 2013 Mar;
7(3):637-46.
PMID: 23506979
The backbone of current cytotoxic treatment of metastatic colorectal cancer (mCRC) consists of a fluoropyrimidine together with either oxaliplatin (XELOX/FOLFOX) or irinotecan (XELIRI/FOLFIRI). With an overall objective response rate of...
4.
Romer M, Larsen L, Offenberg H, Brunner N, Lademann U
Neoplasia
. 2008 Sep;
10(10):1083-91.
PMID: 18813358
High levels of plasminogen activator inhibitor (PAI-1) in tumors are associated with poor prognosis in several cancer types, and the reason for this association is not fully understood. Plasminogen activator...
5.
Lademann U, Romer M, Jensen P, Hofland K, Larsen L, Christensen I, et al.
Eur J Cancer
. 2005 May;
41(7):1095-100.
PMID: 15862760
Plasminogen activator inhibitor-1 (PAI-1) inhibits the activation of the plasminogen activator system, the latter being involved in cancer growth and dissemination. Interestingly, PAI-1 is elevated in many solid tumours and...